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Neural-tube defects (NTD) are common congenital malformations that can lead to severe
disability or even death. Periconceptional supplementation with the B-vitamin folic acid has
been demonstrated to prevent 50–70% of NTD cases. Since the identification of the first
genetic risk factor of NTD, the C677T single-nucleotide polymorphism (SNP) in the methyl-
enetetrahydrofolate reductase (MTHFR) gene, and the observation that elevated plasma
homocysteine levels are associated with NTD, research has focused on genetic variation in
genes encoding for enzymes of folate metabolism and the closely-related homocysteine meta-
bolism. In the present review relevant SNP in genes that code for enzymes involved in folate
transport and uptake, the folate cycles and homocysteine metabolism are summarised and the
importance of these SNP discussed in relation to NTD risk.
Neural-tube defects: Folate: Genetic variation
Neural-tube defects (NTD) are common, costly and
frequently fatal congenital anomalies with an aetiology that
remains elusive. All infants with anencephaly are stillborn
or die shortly after birth, whereas many infants with spina
bifida survive, usually as a result of extensive medical and
surgical care. Infants with spina bifida who survive are
likely to have severe lifelong disabilities and are at risk for
psycho-social maladjustment.
The causes of NTD are multifactorial. The evidence for
genetic predisposition as a determinant for NTD is: a
preponderance of NTD in females; prevalence differences
related to racial and ethnic background (Buccimazza et al.
1994; Chatkupt et al. 1994); an increased prevalence in
siblings (Hall et al. 1988). Environmental risk factors for
NTD are the use of anti-epileptic drugs such as valproic
acid (Lammer et al. 1987) and maternal conditions such as
diabetes (Becerra et al. 1990), hyperthermia (Edwards
et al. 1995; Graham et al. 1998), obesity (Shaw et al. 1996;
Watkins et al. 1996; Werler et al. 1996) and certain pro-
fessions e.g. agriculture or cleaning (Blatter et al. 1996).
One of the most promising clues to the causes of NTD is
that women who use folic acid periconceptionally are at a
50–70% reduced risk for NTD-affected pregnancies (Smi-
thells et al. 1980; Vitamin Study Research Group, 1991;
Czeizel & Dudas, 1992). In an attempt to unravel the
molecular mechanism underlying this protective effect of
periconceptional folic acid supplementation, research on
NTD has focused on folate uptake, the folate cycles and
the closely-related homocysteine (Hcy) metabolism. The
present review will focus on the genetics of NTD, in par-
ticular genetic variation in genes encoding for enzymes
related to the folate pathway and Hcy metabolism.
Folate transport and uptake
Dietary folates mainly exist as polyglutamates (Tamura
& Stokstad, 1973). As the uptake and transport of folates
in the body occurs as monoglutamates, the dietary
polyglutamated folates have to be deconjugated to
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monoglutamates before absorption. The enzyme respon-
sible for this deconjugation is folylpoly-g-glutamate car-
boxypeptidase, which is associated with the intestinal
apical brush border (Chandler et al. 1991) and is encoded
by the glutamate carboxypeptidase II (GCPII) gene. After
the deconjugation process the folate monoglutamates are
absorbed in the proximal small intestine via a mechanism
that involves reduced folate carrier (RFC). Once folate has
entered the bloodstream it is mainly present as 5-methyl-
tetrahydrofolate (THF) monoglutamate, which can enter
the cell by means of folate receptor (FR) a. FR-a is a
glycosylphosphatidylinositol-linked glycoprotein with a
high affinity for the monoglutamate 5-methylTHF (Wang
et al. 1992) and is expressed in a limited number of
epithelial cells, predominantly in the proximal tubules
of the kidney, the choroid plexus and the placenta (Kamen
& Smith, 2004). The other FR, FR-b and FR-g , possess
a lower affinity for 5-methylTHF than FR-a. Besides
receptor-mediated transport, 5-methylTHF can also enter
the cell by carrier-mediated transport via RFC. In contrast
to FR-a, RFC is ubiquitously expressed, although the
affinity of RFC for 5-methylTHF is lower than that of
FR-a. To retain the folate in the cell the enzyme folyl-
polyglutamate synthase adds glutamyl groups to the
existing glutamyl group of folate, as polyglutamates are
poorly transported across the cell membrane.
Genetic variation
Glutamate carboxypeptidase II
Genetic variation has been demonstrated in the GCPII
gene. It has been reported (Devlin et al. 2000) that the
C1561T single-nucleotide polymorphism (SNP) in the
GCPII gene (His475Tyr) leads to a reduced activity of the
folylpoly-g-glutamate carboxypeptidase enzyme and sub-
sequently decreased plasma folate levels and increased
plasma Hcy levels. In contrast to these data Afman et al.
(2003b) observed that the C1561T SNP results in increased
plasma folate levels and they could not demonstrate an
association between this SNP and NTD risk. Furthermore,
other studies (Lievers et al. 2002; Morin et al. 2003a;
Relton et al. 2003) have failed to find an effect of the
GCPII C1561T SNP on NTD risk or metabolite levels.
Parenthetically, the supplemented form of folate, folic
acid, is a synthetic monoglutamate and does not require
folylpoly-g-glutamate carboxypeptidase to be absorbed.
The use of periconceptional folic acid supplementation
could thus attenuate possible effects of genetic variation in
the GCPII gene.
Folate receptors a and b
Folate mainly enters the cell via FR-a, and the importance
of FR-a is demonstrated by the observation that folate-
binding protein 1 (the mouse orthologue of human FR-a)
nullizygosity is embryonically lethal in knock-out mice
(Piedrahita et al. 1999). Barber et al. (1998) have investi-
gated the molecular genetic variation within the FR-a gene
among a group of newborns with spina bifida. Using
single-stranded conformation polymorphism analysis,
dideoxy fingerprinting and sequence analysis they were
unable to find any variation in exons 3–6 encoding for the
mature protein. Furthermore, an analysis of the total
coding region including the intron–exon boundaries and
the signal sequences of human FR-a and FR-b in thirty-
nine spina bifida patients, forty-seven mothers with a spina
bifida-affected child and ten controls has also failed to
identify any variation (Heil et al. 1999). Recently, two
SNP in the 50-untranslated region of the FR-a have been
reported, both with a low prevalence (approximately 0.4%
each; Nilsson & Borjel, 2004).
O’Leary et al. (2003) have focused on the FR-b gene
instead of the FR-a gene and have examined five SNP in
the FR-b gene that were present in the available database.
Four of these SNP were not identified in their study
population. However, they did confirm the presence of an
A!T substitution in intron 1 with a high allele frequency,
but no association with NTD risk was found.
The coding regions of the FR-a and FR-b genes do not
show any variation. Some variants have been identified in
the untranslated regions of these two genes, but none of the
variation identified so far has been associated with NTD
risk. It is possible that the FR genes do not tolerate any
variation in their coding regions, and variants in the FR
genes may not be compatible with life. This possible
explanation is supported by data from the folate-binding
protein 1-knock-out mouse model (Piedrahita et al. 1999).
Rothenberg et al. (2004) have recently identified the
presence of autoantibodies directed against FR in the
serum of women whose pregnancy is or was complicated
by NTD. The autoantibodies were shown to block the
binding of folic acid to the FR and to inhibit folate uptake
by KB cells, a human epidermoid carcinoma cell line. An
additional amount of folate could theoretically overcome
this blockage, and thus the presence of FR autoantibodies
may explain part of the preventive effect of periconcep-
tional folic acid supplementation (Rothenberg et al. 2004).
The findings of this study are promising; however, the
study population was small and additional studies in larger
populations are necessary to determine the exact role of FR
autoantibodies in the aetiology of NTD.
Reduced folate carrier
An A80G substitution has been identified in the RFC-1
gene that leads to the replacement of a histidine by an
arginine (His27Arg; Chango et al. 2000). Shaw et al.
(2002) have reported the absence of an association between
the RFC-1 A80G SNP and spina bifida risk in children,
although they did observe a possible increase in spina
bifida risk for children whose mothers did not use folic
acid periconceptionally. De Marco et al. (2003) have
identified the A80G SNP in the RFC-1 gene as a risk factor
for NTD in both patients and their mothers. A study in a
Chinese population has reported an increased NTD risk in
patients with the G80G genotype, especially when their
mothers did not take folic acid supplements (Pei et al.
2005). Other studies (Relton et al. 2003, 2004a,b) have
failed to find an association between the RFC-1 A80G SNP
and maternal NTD risk, although one study (Morin et al.
2003a) has demonstrated an association between the
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RFC-1 G80G genotype and low erythrocyte folate levels.
In summary, the RFC-1 A80G SNP may be a NTD risk
factor, especially when maternal folate status is low, sug-
gesting that sufficient folate can attenuate the effect of this
polymorphism.
Folate cycle
On entering the cell 5-methylTHF functions as a methyl
donor for the remethylation of Hcy to methionine, with
subsequent formation of THF (Fig. 1). The THF formed
after the demethylation of 5-methylTHF is used as a
substrate in several reactions. THF can be converted to
10-formylTHF via a reversible reaction catalysed by for-
mylTHF synthase, which is one of the three enzymic
properties of the tri-functional enzyme methyleneTHF
dehydrogenase (MTHFD). The other two enzymic proper-
ties of MTHFD are methenylTHF cyclohydrolase that
reversibly converts 10-formylTHF to 5,10-methenylTHF
and MTHFD that reversibly converts 5,10-methenylTHF to
5,10-methyleneTHF (Hum et al. 1988). Thus, the MTHFD
enzyme plays a central role in the folate metabolism
(Fig. 1). Folate metabolism acts as a C1 unit donor in the
synthesis of the purines adenine and guanine, which are
building blocks for DNA. Another DNA building block is
thymidine, the synthesis of which is catalysed by the
enzyme thymidylate synthase (TS). In this reaction 5,10-
methyleneTHF donates a methylene group to dUMP to
form dTMP and dihydrofolate (DHF). The DHF is reduced
back to THF by the enzyme DHF reductase (DHFR).
The enzyme serine hydroxymethyltransferase (SHMT)
catalyses the reversible conversion of serine and THF to
glycine and 5,10-methyleneTHF (Fig. 1) and is present in
two isoforms, i.e. a cytosolic and a mitochondrial form.
Both enzymes require pyridoxal phosphate, an active form
of vitamin B6 (Stover et al. 1997). The 5,10-methyl-
eneTHF can be further reduced to 5-methylTHF by the
enzyme methyleneTHF reductase (MTHFR). This enzyme
is of great importance in the regulation of available folate
for the remethylation of Hcy.
Genetic variation
Methylenetetrahydrofolate dehydrogenase
A study of the MTHFD gene in 117 patients with NTD by
single-stranded conformation polymorphism analysis (Hol
et al. 1998) has identified a G1958A SNP that results in the












































Fig. 1. Simplified overview of the folate pathway and homocysteine metabolism. GAR, glycinamide ribonucleotide; FGAR,
formyl glycinamide ribonucleotide; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; FAICAR, formyl 5-aminoimi-
dazole-4-carboxamide ribonucleotide; THF, tetrahydrofolate; DHF, dihydrofolate; DHFR, dihydrofolate reductase; MTHFD,
methylenetetrahydrofolate dehydrogenase; TS, thymidylate synthase; SHMT, serine hydroxymethyltransferase; MTHFR,
methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; BHMT, betaine-
homocysteine methyltransferase; CBS, cystathionine b-synthase; RFC, reduced folate carrier; FR, folate receptor; AdoMet,
S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; B6, pyridoxal 50-phosphate; B12, cobalamin; B2, riboflavin.
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10-formylTHF synthetase domain of the MTHFD enzyme
(Arg653Gln). In this study the G1958A SNP had a similar
frequency among patients with NTD and controls, and did
not influence plasma Hcy concentration. More recently,
in an Irish population it has been shown that the presence
of this Arg653Gln SNP is associated with an increased
risk for mothers to have an NTD-affected child, but not
with an increased NTD risk for the patient (Brody et al.
2002). More studies on the MTHFD Arg653Gln variant
are necessary to determine the influence of this SNP on
NTD risk.
Thymidylate synthase
A 28 bp tandem repeat in the promoter enhancer region of
the TS gene has been identified, typically containing two
or three repeats (Kaneda et al. 1987). The triple repeat
results in increased TS gene expression, whereas the dou-
ble repeat is associated with decreased TS gene expression
(Kaneda et al. 1987; Horie et al. 1995). The repeat is
associated with decreased plasma folate and total plasma
Hcy concentrations in a Chinese population (Trinh et al.
2002); however, no such effect was found in a north-
western European population (Brown et al. 2004). Two
studies (Volcik et al. 2003; Wilding et al. 2004) have
examined the association between the repeat and NTD risk.
Volcik et al. (2003) have shown that the double repeat is
associated with NTD risk in infants, especially in non-
Hispanic US whites, whereas Wilding et al. (2004) were
unable to demonstrate an association between the repeat
and NTD risk in subjects with NTD and their parents.
A 6 bp deletion in the 30-untranslated region has been
suggested to play a role in TS mRNA stability and trans-
lation (Ulrich et al. 2000) and the non-deleted genotype
has been associated with increased NTD risk only in non-
Hispanic US white subjects (Volcik et al. 2003). The only
study that has examined the 6 bp deletion in relation to
plasma Hcy and folate levels (Kealey et al. 2005) has
reported an association between this TS variant and ery-
throcyte folate levels and plasma Hcy levels in non-
smoking individuals. Based on these data, more studies on
the relationship between the TS variants and folate status
and NTD risk are warranted.
Dihydrofolate reductase
All folic acid in vitamin supplements and food fortification
is present in the unreduced form and requires the action
of DHFR before it can participate in cellular processes.
Recently, a 19 bp deletion has been described within
intron-1 of the DHFR gene, which eliminates a potential
SP1 transcription factor-binding site, possibly affecting
DHFR gene expression (Johnson et al. 2004). In this study
the 19 bp deletion was shown to increase the risk of having
a child with spina bifida. These data warrant more studies
on the association between the 19 bp deletion in the DHFR
gene and NTD risk.
Serine hydroxymethyltransferase
A study has been conducted to identify genetic variation in
both the cytosolic and mitochondrial isoforms of the SHMT
gene in seventy patients with NTD (Heil et al. 2001).
Several SNP were identified, of which the C1420T sub-
stitution in the cytosolic SHMT gene and the 4 bp deletion
in the 30-untranslated region of the mitochondrial isoform
of the SHMT gene were common. The C1420T SNP,
changing a leucine into a phenylalanine (Leu474Phe) in
the cytosolic protein, was not found to be associated with
NTD risk in mothers of patients with NTD, although the
C1420C genotype resulted in elevated plasma Hcy con-
centrations and decreased erythrocyte and plasma folate
levels in the mothers. The 4 bp deletion in the 30-untrans-
lated region of the mitochondrial isoform of the SHMT
gene did not influence NTD risk, nor plasma Hcy and
folate levels (Heil et al. 2001).
Other studies (Relton et al. 2004a,b) that have also
looked at the C1420T SNP in the cytosolic isoform of
SHMT have demonstrated a non-significant protective
effect of the T allele in mothers. The studies of Geisel
et al. (2003) and Relton et al. (2004a) have not shown a
relationship between the C1420T SNP in the cytosolic
isoform SHMT and plasma Hcy and erythrocyte folate. In
conclusion, the C1420T SNP in the cytosolic isoform of
SHMT is at most a minor risk factor for NTD risk.
Methylenetetrahydrofolate reductase
In collaboration with researchers at Montreal Children’s
Hospital, Montreal, Canada, Frosst et al. (1995) have
identified the C677T (Ala222Val) SNP in the MTHFR
gene that results in a mildly dysfunctional ‘thermolabile’
MTHFR enzyme and have demonstrated an association
between the T677T genotype and elevated plasma Hcy
levels. Furthermore, an increase in spina bifida risk for
both mothers and children with the MTHFR T677T geno-
type has been reported (van der Put et al. 1995), thus
identifying the first genetic risk factor for spina bifida.
Following the identification of the MTHFR C677T SNP
many studies have investigated this SNP in relation to
NTD risk. Some results (Mornet et al. 1997; Speer et al.
1997; Koch et al. 1998; Botto & Yang, 2000) have been
contradictory and inconclusive, in part because of the
considerable variation in MTHFR C677T allele frequency
among different geographic regions and ethnicities.
A meta-analysis (van der Put et al. 1997a) on the asso-
ciation between the MTHFR C677T SNP and NTD risk has
been carried out by combining all published data of control
groups and families affected by NTD. Mothers with the
MTHFR T677T genotype were found to have an overall
60% increase in risk of having NTD-affected children
(odds ratio 1.6 (95% CI 1.1, 2.3)) and children with the
MTHFR 677TT genotype were 80% more likely to have
NTD (odds ratio 1.8 (95% CI 1.3, 2.5)). Botto & Yang
(2000) have also conducted a meta-analysis on the MTHFR
C677T SNP in relation to NTD risk. They have reported a
2-fold increase in risk for being a mother of a NTD-
affected child (odds ratio 2.0 (95% CI 1.5, 2.8)) and a 1.8-
fold increased NTD risk (odds ratio 1.8 (95% CI 1.4, 2.2))
for infants who have the MTHFR T677T genotype. In
summary, the MTHFR T677T genotype is a genetic risk
factor for NTD in both patients with NTD and their
mothers.
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A second SNP in the MTHFR gene involves the sub-
stitution of an adenine by a cytosine on position 1298
(A1298C), leading to an amino acid change of a glutamate
into an alanine (Gln429Ala; van der Put et al. 1998). This
SNP has also been associated with decreased MTHFR
enzyme activity, although not as pronounced as that of the
MTHFR C677T SNP (van der Put et al. 1998; Weisberg
et al. 1998; Botto & Yang, 2000). To date, only one study
(De Marco et al. 2002) has found an association between
the MTHFR A1298C SNP and NTD risk, and the SNP does
not seem to influence plasma Hcy and folate levels (van
der Put et al. 1998; Weisberg et al. 1998; Stegmann et al.
1999; Volcik et al. 2000; Cunha et al. 2002; Parle-
McDermott et al. 2003). The MTHFR A1298C SNP is not
likely to be a risk factor for NTD.
Homocysteine metabolism
Remethylation
Remethylation of Hcy by the enzyme methionine synthase
(MTR) takes place in all cells, except the erythrocytes, and
involves the donation of a methyl group from 5-
methylTHF to Hcy leading to the formation of methionine
and THF (Fig. 1). The enzyme MTR requires vitamin B12
(cobalamin; cbl) as a cofactor, and the resulting complex,
cbl(I)MTR, can bind the methyl group of 5-methylTHF to
form methylcbl(III)MTR. The transfer of this methyl group
to Hcy leaves the reformed cbl(I)MTR complex available
for another methyl donation by 5-methylTHF. However,
the cbl(I)MTR complex is sensitive to oxidation into the
inactive cbl(II)MTR complex, which can be reactivated to
the functional methylclb(III)MTR by the enzyme methio-
nine synthase reductase (MTRR) and the donation of a
methyl group from S-adenosylmethionine (Fig. 2).
While the MTR enzyme is expressed in almost every
cell, another Hcy-remethylation system, the betaine-Hcy
methyltransferase (BHMT) enzyme, is mainly expressed in
the liver and kidneys. BHMT can remethylate Hcy by
donating a methyl group from betaine and is responsible
for 50% of the Hcy remethylation.
Vitamin B12 uptake, transport and metabolism
In plasma only 20% of the total vitamin B12 is bound to
holo-transcobalamin (TC), the remaining 80% is bound
to holo-haptocorrin and is not available for cellular uptake.
Only vitamin B12 bound to TC is recognised by a specific
carrier and taken up by the cell (Fig. 2), and the function of
holo-haptocorrin is not clear. Thus, plasma holo-TC con-
centrations may be a better indicator of vitamin B12 status
than total plasma vitamin B12 levels (holo-TC+ holo-
haptocorrin). In the cell vitamin B12 is converted into
two metabolically-active forms, i.e. methylcbl required
as a cofactor for MTR, which is present in the cytosol,
and 50-deoxyadenosylcbl necessary for the function of
methylmalonyl-CoA mutase, which is present in the mito-
chondria (Fig. 2) and converts L-methylmalonyl-CoA to
succinyl-CoA. As a metabolic consequence, vitamin B12
deficiency will result in elevated plasma Hcy levels and
elevated plasma methylmalonic acid (Elin & Winter,
2001).
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Fig. 2. Vitamin B12 pathway. cbl, Cobalamin; IF, intrinsic factor; HC, haptocorrin; TC, transcobalamin; mutase, L-methylma-
lonyl-CoA mutase; Met, methyl; THF, tetrahydrofolate; MTR, methionine synthase; Hcy, homocysteine.
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Transmethylation
Methionine adenosyltransferase catalyses the biosynthesis
of S-adenosylmethionine from methionine and ATP.
Methionine adenosyltransferase is present in two isoforms;
one form is encoded by the methionine adenosyltransferase
2a gene, which is present in nearly all tissues, and the other
form is encoded by the methionine adenosyltransferase 1a
gene, which is expressed only in the liver. S-adenosyl-
methionine is the ultimate source of methyl groups for
methylation reactions of, for example, DNA, RNA, pro-
teins and lipids. The transfer of a methyl group from
S-adenosylmethionine to a methyl acceptor results in the
formation of S-adenosylHcy, which is hydrolysed to ade-
nosine and Hcy by the enzyme S-adenosylHcy hydrolase.
The equilibrium of this reversible reaction favours S-ade-
nosylHcy formation, which is an allosteric inhibitor of
methylation. Thus, Hcy and adenosine need to be metab-
olised rapidly in order to maintain low S-adenosylHcy
levels.
Trans-sulfuration
In the transmethylation and remethylation pathway Hcy is
retained. In the trans-sulfuration pathway Hcy is irrever-
sibly degraded to cysteine by two pyridoxal phosphate-
dependent enzymes, i.e. cystathionine b-synthase (CBS),
which catalyses the condensation of serine and Hcy to
cystathionine, and g-cystathionase, which catalyses the
hydrolysis of cystathionine to cysteine and a-ketobutyrate.
Genetic variation
Methionine synthase
Sequencing analysis of the coding region of the MTR gene
(van der Put et al. 1997b) has revealed a A2756G SNP,
changing an aspartic acid residue (believed to be part of
a helix involved in cofactor binding) to a glycine
(Asp919Gly). Several studies have examined the MTR
A2756G SNP in relation to NTD. In some of these studies
the presence of the G allele has been shown to be associ-
ated with an increased risk for the mother to have a child
with NTD (Doolin et al. 2002), an increased NTD risk in
the child (Gueant-Rodriguez et al. 2003; Zhu et al. 2003)
or both (Gos et al. 2004). However, in other studies no
association between the MTR SNP and NTD risk has been
found (van der Put et al. 1997b; Morrison et al. 1998;
Lucock et al. 2000, 2001; De Marco et al. 2002), while in
one study the MTR 2756GG genotype has been found to be
associated with a decreased NTD risk in the patients
(Christensen et al. 1999).
Plasma Hcy levels have been reported in some studies to
be increased for the MTR 2756AA genotype (Harmon et al.
1999; Tsai et al. 2000), although the relationship is not
always significant (Chen et al. 2001; Kluijtmans et al.
2003), and in other studies it is present (van der Put et al.
1997b; Jacques et al. 2003; Klerk et al. 2003). The MTR
A2756A genotype does not seem to influence plasma folate
levels (Harmon et al. 1999; Jacques et al. 2003; Klerk
et al. 2003; Kluijtmans et al. 2003), although one study has
reported increased plasma folate levels for the MTR
G2756G genotype (Chen et al. 2001). Data on the asso-
ciation between the MTR A2756G SNP and plasma Hcy
and plasma folate concentrations as well as the relationship
between this polymorphism and NTD risk are incon-
clusive. If there is a relationship between the MTR
A2756G SNP and NTD risk, it is at most a rather moderate
association.
Methionine synthase reductase
Wilson et al. (1999) have described a common variant in
the FMN-binding domain of the gene encoding for the
MTRR enzyme; the A66G SNP, which leads to an amino
acid substitution of an isoleucine by a methionine
(Ile22Met). They have reported an increased NTD risk for
both mothers and patients with the MTRR G66G genotype,
but only when plasma vitamin B12 concentration is low
(Wilson et al. 1999). A later study (Zhu et al. 2003) has
reported that the MTRR 66AG/GG genotype is associated
with an increase in NTD risk for both mothers and patients.
In a Polish study the association between the MTRR 66GG
genotype and NTD risk was found to be confined to
lumbosacral NTD (Pietrzyk et al. 2003). In other studies
(Wilson et al. 1999; Lucock et al. 2001; Gos et al. 2004;
O’Leary et al. 2005) the MTRR 66GG genotype was not
found to be significantly associated with NTD risk for
mothers and their children. In contrast to the previously
discussed data, Relton et al. (2004a,b) have designated the
A allele as a risk factor for NTD; however, the MTRR
genotype distribution was not in Hardy-Weinberg equilib-
rium. Using a transmission disequilibrium test Doolin
et al. (2002) have also shown that the A allele is a risk
factor for NTD, but only in mothers. Recently, a study was
carried out into the association between the MTRR A66G
polymorphism and spina bifida risk (IJM van der Linden,
M den Heijer, LA Afman, H Gellenkink, SHHM Vermeu-
len, LAJ Kluijtmans and HJ Blom, unpublished results).
It was shown that the MTRR G66G genotype is a risk
factor for spina bifida in mothers, and after performing a
transmission disequilibrium test for eighty-two complete
triads no preferential transmission of the MTRR risk
allele from parents to their spina bifida-affected child was
identified. A meta-analysis of eight relevant studies on the
relationship between the MTRR A66G variant and maternal
NTD risk has demonstrated the MTRR G66G genotype to
be associated with an overall 48% increase in NTD risk in
mothers (odds ratio 1.48 (95% CI 1.00, 2.19); IJM van der
Linden, M den Heijer, LA Afman, H Gellenkink, SHHM
Vermeulen, LAJ Kluijtmans and HJ Blom, unpublished
results).
Olteanu et al. (2002, 2004) have shown that the sub-
stitution of an isoleucine by a methionine at position 22
in the MTRR enzyme results in a less-efficient repair of
the MTR, possibly as a result of a reduced affinity for
this enzyme. The MTRR A66G SNP has been associated
with elevated plasma Hcy levels (Gaughan et al. 2001,
2002), although in most studies (Wilson et al. 1999;
Jacques et al. 2003; Kluijtmans et al. 2003; Feix et al.
2004) an effect of the MTRR SNP on plasma Hcy has not
been observed.
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In summary, the MTRR G66G genotype seems to be a
NTD risk factor in mothers, without altering plasma Hcy
concentration.
Transcobalamin
TC transports vitamin B12 into the cell, where it is used as
a cofactor in Hcy remethylation and L-methylmalonyl-CoA
conversion. Decreased TC saturation with vitamin B12 has
been reported in mothers with children with NTD (Afman
et al. 2001). Furthermore, Afman et al. (2002) identified
five sequence variants in the TC gene, of which the C776G
SNP (Pro259Arg) has been described previously (Li et al.
1994). An analysis of the frequency of each SNP has been
conducted in a population comprising mothers of NTD-
affected children and controls (Afman et al. 2002). None
of the SNP was found to be associated with NTD risk or
with plasma Hcy concentration, although a trend was
observed for the C776G SNP and elevated Hcy levels. The
C776G SNP was shown to be associated with low total-
TC, holo-TC and apo-TC levels and with a decreased holo-
TC:total-TC that could be explained by a reduced binding
of vitamin B12 to TC (Afman et al. 2002). The effect of
this variant on TC level and saturation has been confirmed
in a different study population (Miller et al. 2002).
Other studies have also investigated the relationship
between genetic variants in the TC gene and NTD risk.
Pietrzyk & Bik-Multanowski (2003) have shown that the
G776G genotype is associated with an increase in maternal
NTD risk, whereas studies by Gueant-Rodriguez et al.
(2003) and Swanson et al. (2005) have found no such
effect of the C776G SNP or the other SNP in the TC gene
on NTD risk. Furthermore, no relationship between the
TC C776G SNP and plasma Hcy concentrations has been
found (Geisel et al. 2003; Winkelmayer et al. 2004;
Gueant-Rodriguez et al. 2005; von Castel-Dunwoody et al.
2005). In summary, the TC C776G SNP does not seem to
be a NTD risk factor.
Betaine-homocysteine methyltransferase
An analysis of the BHMT gene (Heil et al. 2000) has
identified the G595A SNP (Gly199Ser), the G716A
(Arg239Gln) SNP previously reported by Park & Garrow
(1999) and the G1218T (Gln406His) SNP, but has not
established an association between any of these SNP and
plasma Hcy levels. A more recent study (Weisberg et al.
2003) has also found no relationship between the G716A
SNP and plasma Hcy concentrations. However, the G716A
SNP has been shown to be associated with a decrease in
NTD risk in both children and mothers (Morin et al.
2003b), although a recent study (Zhu et al. 2005) did not
find a protective effect of the A716A genotype in patients
with NTD.
In mouse embryos BHMT is not expressed until neural-
tube closure is almost completed (Fisher et al. 2002),
which makes it less likely that the BHMT G716A SNP
will be a risk factor of NTD in the fetus. Since the
BHMT enzyme is responsible for 50% of the liver Hcy
remethylation, variation in the maternal BHMT gene could
affect maternal Hcy metabolism, thereby influencing the
risk of having NTD-affected offspring.
Cystathionine b-synthase
Although CBS is only expressed in the liver and kidneys,
it has been reported (Quere et al. 1999) that CBS is
Table 1. Genetic variants in genes related to the folate cycles and homocysteine metabolism
Gene SNP
Amino acid
substitution Allele frequency NTD
GCPII C1561T* His475Tyr approx 0.06 (T) -
RFC-1 A80G His27Arg 0.46–0.56 (G) + / -
MTHFD G1958A* Arg653Gln 0.41–0.46 (A) + / -
TS 28 bp rpt 0.17–0.48 (two rpt) + / -
6 bp del 0.29–0.42 (del) + / -
DHFR 19bp del 0.45 (del) +
cSHMT C1420T Leu474Phe 0.32–0.36 (T) -
mSHMT 4bp del 0.02 (del) -
MTHFR C677T* Ala222Val 0.10–0.50 (T) +
A1298C* Glu429Ala 0.25–0.40 (C) -
MTR A2756G Asp919Gly 0.15–0.20 (G) + / -
MTRR A66G Ile22Met 0.39–0.59 (G) +
TC C776G Pro259Arg approx 0.45 (G) -
BHMT G716A Arg239Gln 0.25–0.37 (A) + / -
CBS 844ins68 approx 0.09 (ins) -
31 bp VNTR approx 0.77
(eighteen rpt) -
SNP, single-nucleotide polymorphism, NTD, neural-tube defect; GCPII, glutamate carboxypeptidase II; RFC-1, reduced folate carrier-1; MTHFD,
methylenetetrahydrofolate dehydrogenase; TS, thymidilate synthase; DHFR, dihydrofolate reductase; cSHMT, mSHMT, cytosolic and mitochondrial serine
hydroxymethyltransferase respectively; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methionine synthase reductase; TC,
transcobalamin; BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine b-synthase; del, deletion; ins, insertion; rpt, repeat; VNTR, variable number
of tandem repeats; approx, approximately; + , positive relationship with SNP; - , no relationship with SNP; + / - , possible relationship with SNP.
*Coding position is not according to nomenclature.
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expressed during early embryogenesis, and variation in the
CBS gene may thus influence embryogenesis.
The 68 bp insertion (844ins68) and the 31 bp variable
tandem repeat (VNTR) in the CBS gene are the most-
frequently-studied variations in relation to NTD. In most
studies the 844ins68 is not associated with NTD risk in
children or mothers (Ramsbottom et al. 1997; Morrison
et al. 1998; Speer et al. 1999; Richter et al. 2001; Gos
et al. 2004), although there may be a trend towards a
protective effect (Akar et al. 2000; Richter et al. 2001).
A possible gene–gene interaction between the MTHFR
C677T polymorphism and the CBS 844ins68 has also been
examined in relation to NTD, but no such association
has been reported (Ramsbottom et al. 1997; Morrison
et al. 1998; Speer et al. 1999; Richter et al. 2001).
In conclusion, the CBS 844ins68 does not seem to be a
NTD risk factor.
The 31 bp VNTR has been described by Kraus et al.
(1998) and further characterised by Lievers et al. (2001).
It has also been shown (Lievers et al. 2001) that the 31 bp
VNTR results in alternative splicing and a subsequent
decrease in enzyme activity that is negatively correlated
with the number of repeat units, while the number of
repeat units is positively associated with plasma Hcy con-
centrations. A more recent study (Afman et al. 2003a) has
also demonstrated that the 18/18 VNTR genotype is asso-
ciated with elevated plasma Hcy levels when compared
with the 17/18 and 18/19 VNTR genotypes. In addition, it
has been reported that plasma Hcy levels decrease in
individuals with the 16/17 and 17/18 VNTR genotypes
compared with the 17/17 VNTR genotype (Yang et al.
2000). However, the 31 bp VNTR does not influence the
risk of NTD (Afman et al. 2003a).
Conclusions
Since the observation that periconceptional folic acid sup-
plementation reduces the risk of having a NTD-affected
pregnancy by 50–70% and the identification of the first
genetic risk factor of NTD (i.e. the C677T SNP in the
MTHFR gene), research on these birth defects has focused
on genetic variation in genes encoding for the enzymes
involved in the folate cycles and the closely-related Hcy
metabolism. Many genetic variants have been identified,
but only a few of these variants have been associated with
NTD risk (see Table 1). Of all variants discussed in the
present review the MTHFR C677T SNP and the MTRR
A66G SNP are the only two SNP that can be considered
risk factors for NTD. Other genetic variants reported in the
present review are less likely to be associated with NTD
risk. More studies in sufficiently large populations are
required to determine possible associations between most
of these SNP and NTD risk.
In order to identify new genetic determinants of NTD,
investigation of other genes that are not related to the
folate pathway and Hcy metabolism may be required. New
strategies, such as the SNP array that enables the identifi-
cation of thousands of polymorphisms at the same time,
can be used in future research to identify new genetic risk
factors of NTD.
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